We have located links that may give you full text access.
Metabolic effects and safety of Roux-en-Y gastric bypass surgery versus conventional medication in obese Chinese patients with type 2 diabetes.
Diabetes/metabolism Research and Reviews 2019 Februrary 11
AIM: To assess metabolic effects and safety of Roux-en-Y gastric bypass (RYGB) versus conventional medication (CM) in obese Chinese patients with type 2 diabetes (T2DM).
METHODS: This retrospective cohort study included 40 patients who underwent RYGB (mean age 44.1 years, body mass index (BMI) 33.3 kg/m2 ) and 36 patients administered CM (mean age 49.4 years, BMI 32.1 kg/m2 ). The primary endpoint was achievement of the triple endpoint (hemoglobin A1C (HbA1c) <7.0%, low-density lipoprotein cholesterol <2.6 mmol/L, and systolic blood pressure <130 mmHg). Changes in weight, BMI, medication usage, complications, and adverse events were assessed.
RESULTS: After 1-year follow-up, 35% of RYGB patients and 8% of CM patients achieved the triple endpoint (P=0.005). More patients in the RYGB group achieved complete (48% vs. 3%, P<0.001) and partial (23% vs. 0%, P=0.007) remission of diabetes, and complete remission of hypertension (58% vs. 24%, P=0.019). Patients in the RYGB group had greater weight loss and decrease in BMI, waist circumference, fasting and postprandial of blood glucose and insulin levels, HbA1c, blood pressure, triglycerides, and increased high density cholesterol (P<0.001-<0.05). A lower proportion of the RYGB group received antidiabetics, antihypertensives, or antilipemic treatments, and had non-alcoholic fatty liver disease (NAFLD) than the CM group during follow-up. More patients had nutrient deficiency related diseases in the RYGB group over 1-year follow-up.
CONCLUSIONS: For obese Chinese patients with T2DM, RYGB resulted in better metabolic control, greater weight loss, and lower medication usage and NAFLD, but more frequently resulted in diseases related to nutrient deficiency.
METHODS: This retrospective cohort study included 40 patients who underwent RYGB (mean age 44.1 years, body mass index (BMI) 33.3 kg/m2 ) and 36 patients administered CM (mean age 49.4 years, BMI 32.1 kg/m2 ). The primary endpoint was achievement of the triple endpoint (hemoglobin A1C (HbA1c) <7.0%, low-density lipoprotein cholesterol <2.6 mmol/L, and systolic blood pressure <130 mmHg). Changes in weight, BMI, medication usage, complications, and adverse events were assessed.
RESULTS: After 1-year follow-up, 35% of RYGB patients and 8% of CM patients achieved the triple endpoint (P=0.005). More patients in the RYGB group achieved complete (48% vs. 3%, P<0.001) and partial (23% vs. 0%, P=0.007) remission of diabetes, and complete remission of hypertension (58% vs. 24%, P=0.019). Patients in the RYGB group had greater weight loss and decrease in BMI, waist circumference, fasting and postprandial of blood glucose and insulin levels, HbA1c, blood pressure, triglycerides, and increased high density cholesterol (P<0.001-<0.05). A lower proportion of the RYGB group received antidiabetics, antihypertensives, or antilipemic treatments, and had non-alcoholic fatty liver disease (NAFLD) than the CM group during follow-up. More patients had nutrient deficiency related diseases in the RYGB group over 1-year follow-up.
CONCLUSIONS: For obese Chinese patients with T2DM, RYGB resulted in better metabolic control, greater weight loss, and lower medication usage and NAFLD, but more frequently resulted in diseases related to nutrient deficiency.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app